Febreze expands home collection with new diffuser
CINCINNATI The Febreze home collection is expanding its line of premium scented home decor items with a no spill wood diffuser.
The no spill wood diffuser technology allows Febreze scented oils to be absorbed into the wood and then diffuse through the air for an authentic scent experience without the worry or hassle of spills. The decorative product joins the likes of Febreze Flameless Luminaries, soy candles and room spray to complement the complete Febreze home collection of products that allow consumers to accent their homes with modern design and authentic fragrances.
“Febreze is always looking to create innovative air care products that meet the needs of our target consumer,” said Chad Brizendine, assistant brand manager, Febreze. “The no spill wood diffuser is a great addition to the Febreze home collection and will allow scent and decor-lovers to experience the premium decor products one would find at specialty stores right in the aisle of their local mass retailer.”
In support of the new product launch, Febreze is partnering with Brooke Burke, mom correspondent on the daytime talk show “The Doctors,” host of TV Land’s, “She’s Got the Look” and “mom-prenuer” and co-CEO of the online community for the woman behind the mom ModernMom.com.
The Febreze no spill wood diffuser is available in willow blossom, pomegranate mango, green tea citrus and honeysuckle orchid scents. The new product and the entire Febreze home collection only is available at Walmart from now through September and then at major retailers nationwide starting in September, with the suggested prices ranging from $14.99 to $16.99.
FDA to have Genzyme plant inspected, reviewed
CAMBRIDGE, Mass. Genzyme Corp. will have to submit to inspections of one of its plants by the Food and Drug Administration and pay fees to the agency under a consent decree, the biotechnology company said Wednesday.
The FDA will likely hire a third party to inspect and review Genzyme’s plant in the Boston neighborhood of Allston for an extended period of time to ensure its compliance with accepted manufacturing standards. Genzyme will also have to pay the FDA for the inspections, and may have to pay other fees as well.
The action comes as a result of an incident in June 2009, when the company detected a virus that inhibits cell growth in one of the containers it uses to manufacture drugs; the virus, vesivirus 2117, is not known to cause human infection. The company said the virus was the cause of declines in productivity at two of its plants, including Allston, in 2008, and was likely introduced via a nutrient used in the manufacturing process.
In November 2009, the company found particulate matter in supplies of drugs from the Allston plant, particularly the Gaucher disease drug Cerezyme (imiglucerase), the Fabry disease drug Fabrazyme (agalsidase beta), the Pompe disease drug Myozyme (alglucosidase alfa), the mucopolysaccharidosis treatment Aldurazyme (laronidase) and the thyroid disease drug Thyrogen (thyrotropin alfa).
The drug maker said it expected shipments of the Cerezyme, Fabrazyme and Myozyme, which are manufactured at the Allston plant, to continue uninterrupted.
SVP product development and clinical operations
HAYWARD, Calif. A company that develops drugs for inflammatory diseases has made a new executive appointment.
Anthera Pharmaceuticals announced that it hired Georgina Kilfoil for the newly-created position of SVP product development and clinical operations. Prior to working for Anthera, Kilfoil was a consultant at InClin and VP alliances and project management at Peninsula Pharmaceuticals.
“Georgina brings over 18 years of project management and clinical research expertise, making her a valuable and welcome addition to our senior management team,” Anthera president and CEO Paul Truex said in a statement.